Links

Homepage

Stock List

Search by Ticker

News

Login

Amgen Inc. (NASDAQ:AMGN)
Stock Analysis

AMGN234.65
▼ -1.48%-3.52

Stock Analysis

The following stock analysis is based on 7.3 years of data (i.e. since May 07, 2013). All the stock history has been downloaded.

Stock Exchange

Amgen Inc. trades on the NasdaqGS exchange in USD dollars.

Sector

It is in the sector.

Current Status of Amgen Inc.

It is currently trading at $234.65 ($238.17 the previous day).It pays a 2.56% dividend.

Financials

The next reporting date is in 83 days (2020 11 03).

CNN estimates profits for the upcoming quarter will be $3.80 per share ($6.4B). The current Canada / US exchange rate is 1.3298.



Over the past 12 months, $0 worth of shares have been purchased and $11580931 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 6.9% per year assuming steady exponential growth. The actual 5 year average is 7.62. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year222.85578437517.8+ Above Average
2 year189.220483870974.4- Below Average
3 year181.1786554621811.2+ Above Average
4 year162.959676113364.6- Below Average
5 year155.816996197720.1- Below Average
Amgen Inc. is projected by analysts to get to $269.00 within the next 12 months (14.6%), but preticted targets range from as high as $308.00 (31.3%) and as low as $185(-21.2%).

Risk

The worst drop it has had in recent years is -25.1%. It has a shape to the stock curve, which means

Stock shape test

DAYS AG0PRICE
10253.65DROPPING
30258.24DROPPING
60225.67RISING
150206.8RISING
365196.25RISING
800183.57RISING
1200162.72RISING
1600148.76RISING
2000154.24DROPPING


With an average increase of 6.9% year over year, if Amgen Inc. is bought at the worst time, Stockmarketizer analysts estimate it will take 43.7 months before the stock will recover to the original purchase price. The P/E value is 19.17.

Tradingview BuySell Widget

Yahoo News Feed

Omeros Reports Coronavirus Treatment Success; Stock Soars

Mon, 10 Aug 2020 13:01:23 Small Omeros on Monday reported success with a test of its corononavirus treatment, saying it helped the recovery of six patients severely ill with Covid-19.... Read Full Article

Bristol Myers Squibb Earnings Top After Drug Giant Wins Key Patent Fight

Thu, 06 Aug 2020 20:10:23 Bristol Myers Squibb earnings topped second-quarter analyst estimates early Thursday, after the drug giant and Pfizer won a patent fight for key drug Eliquis. BMY stock rose on the news.... Read Full Article

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

Tue, 04 Aug 2020 12:29:12 Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.... Read Full Article

AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments

Mon, 03 Aug 2020 11:56:00 AbbVie Inc. , Amgen Inc. , and Takeda Pharmaceutical Co. Ltd. announced they started enrolling patients in a clinical trial testing three of their drugs as treatments for severely ill and hospitalized COVID-19 patients. This includes the still investigational HIV therapy cenicriviroc, ...... Read Full Article

Members Of The COVID RandD Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial

Mon, 03 Aug 2020 11:30:00 Today, members of the COVID RandD; Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID ...... Read Full Article

FOCUS-Next big COVID-19 treatment may be manufactured antibodies

Mon, 03 Aug 2020 11:00:00 As the world awaits a COVID-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders - antibodies designed specifically to attack this new virus. Development ...... Read Full Article

Rival drugmakers launch joint trial of medicines for COVID-19

Mon, 03 Aug 2020 09:45:00 Rival drugmakers AbbVie Inc, Amgen Inc and Takeda Pharmaceuticals Inc on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused ...... Read Full Article

Amgen Inc. -- Moodyand's assigns Baa1 rating to Amgenand's new sr. unsecured notes; stable outlook

Thu, 30 Jul 2020 14:24:08 Moody's Investors Service ("Moody's") assigned a Baa1 rating to the new senior unsecured notes of Amgen Inc. ("Amgen") that will be offered in exchange, together with a cash payment, for a series of existing notes. There are no changes to ...... Read Full Article

Amgen Commences Exchange Offers For Certain Series Of Outstanding Senior Notes From Exchange Eligible Holders

Thu, 30 Jul 2020 11:59:00 Amgen Inc. (NASDAQ: AMGN) announced today the commencement of nine separate private offers to exchange (each, an and"Exchange Offerand" and, collectively, the and"Exchange Offersand") certain specified series of its outstanding senior notes (collectively, the and"Old Notesand") for ...... Read Full Article

Analysts Are Updating Their Amgen Inc. (NASDAQ:AMGN) Estimates After Its Second-Quarter Results

Thu, 30 Jul 2020 10:27:06 Shareholders might have noticed that Amgen Inc. (NASDAQ:AMGN) filed its quarterly result this time last week. The...... Read Full Article

Is Adaptive Biotechnologies a Buy?

Thu, 30 Jul 2020 10:19:00 There's nothing like a viral pandemic to remind investors how important it is to understand the human immune system. Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared when the biotech took steps to address the coronavirus pandemic and partnered with Amgen (...... Read Full Article

Biotech Stock Roundup: Amgen Reports Q2, GILDand's CAR T Therapy Gets Approval andand More

Wed, 29 Jul 2020 16:25:04 The biotech sector remains in focus with earnings, regulatory and other pipeline updates.... Read Full Article

Amgen (AMGN) Stock Moves Lower Despite Q2 Earnings Beat

Wed, 29 Jul 2020 15:03:03 Amgen (AMGN) beats Q2 estimates for both earnings and sales. It maintains its previously-issued sales guidance while raising the earnings range. Stock dips.... Read Full Article

Amgen Blows Past EPS Estimates for the Second Quarter

Wed, 29 Jul 2020 14:14:00 Amgen's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. Amgen has a sizable portfolio of medications. Due to coronavirus-related challenges -- the lack ...... Read Full Article

Amgen Inc (AMGN) Q2 2020 Earnings Call Transcript

Wed, 29 Jul 2020 01:30:51 In that context, our results, which includes 6% revenues growth and driven by 13% volume growth, these are strong results and they reflect the resilience of our people, strength of our operating systems, and our success in continuing to supply every patient ...... Read Full Article

Amgen stock heads lower after company Q2and's earnings

Wed, 29 Jul 2020 00:49:00 Shares of Amgen Inc. fell more than 2% in the late session Tuesday after the pharma company reported second-quarter earnings and said the pandemic led to delays in treatments. Amgen said it earned $1.8 billion, or $3.05 a share, compared with $2.18 billion, or $3.57 ...... Read Full Article

Amgen (AMGN) Tops Q2 Earnings and Revenue Estimates

Tue, 28 Jul 2020 21:25:09 Amgen (AMGN) delivered earnings and revenue surprises of 11.55% and 0.39%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Amgen Stock Falls Late After Sales Outlook Remains Unchanged

Tue, 28 Jul 2020 21:18:54 Late Tuesday, Amgen reported second-quarter sales that merely met Wall Street expectations. The giant drugmaker also maintained its revenue guidance for 2020, and Amgen stock fell late.... Read Full Article

Amgen Earnings Beat Wall Street Estimates, but the Stock Still Slips

Tue, 28 Jul 2020 20:51:00 (AMGN)reported earnings Tuesday afternoon that beat Wall Street estimates, but the stock fell 1.6% in after-hours trading. Amgen reported non-GAAP earnings per share of $4.25 for the second quarter, beating the SandP Capital I.Q. Consensus estimate by 48 cents. Amgen shares ...... Read Full Article

Recap: Amgen Q2 Earnings

Tue, 28 Jul 2020 20:25:42 Shares of Amgen (NASDAQ:AMGN) were flat in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 7.05% year over year to $4.25, which beat the estimate of $3.84.Revenue of $6,206,000,000 rose by 5.71% year over year, which beat ...... Read Full Article
<